APOGEE THERAPEUTICS INC (APGE)
Health Care · NASDAQ
Apogee is a clinical-stage biotech developing optimized, extended half-life monoclonal antibodies targeting IL-13, IL-4 receptor alpha, and other inflammatory pathways to treat atopic dermatitis, asthma, and other immunology indications with potential best-in-class dosing.
What APOGEE THERAPEUTICS INC does
Apogee Therapeutics is a clinical-stage biotechnology company developing novel monoclonal antibodies and antibody combinations for inflammatory and immunology (I&I) indications. The company focuses on optimizing antibody engineering to achieve extended half-lives and differentiated dosing—aiming for quarterly or semi-annual maintenance dosing—in major markets including atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. Its pipeline includes four validated targets with multiple monotherapy and combination programs in Phase 1b and Phase 2 clinical trials.
Themes: ["Monoclonal antibodies / biologics"]
Fundamentals
- Price$133.57 as of 2026-07-09 close
- Market cap$10.0B as of 2026-07-10
- 1-year return+266.0% as of 2026-07-09 close
- ROE-32.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.24 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial risk: the safety and efficacy of all product candidates remain unproven in clinical development; Phase 2 and later studies may fail to replicate positive Phase 1b data or may reveal safety issues limiting commercial viability."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.